New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event

scientific article published on 24 July 2020

New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1177/1758835920913801
P932PMC publication ID7383634
P698PubMed publication ID32782484

P50authorF GelsominoQ53282053
Giuseppe LambertiQ87977490
P2093author name stringAndrea Ardizzoni
Michelangelo Fiorentino
Claudio Borghi
Barbara Melotti
Mauro Gargiulo
Francesca Sperandi
Stefano Brocchi
Antonio Poerio
P2860cites workProatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice.Q34582934
Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammationQ35013382
PD-1 and Tim-3 Pathways Regulate CD8+ T Cells Function in AtherosclerosisQ35649732
Increased Risk of Herpes Zoster in Diabetic Patients Comorbid with Coronary Artery Disease and Microvascular Disorders: A Population-Based Study in TaiwanQ35889877
Inflammation and immune system interactions in atherosclerosisQ38083555
Antiinflammatory Therapy with Canakinumab for Atherosclerotic DiseaseQ38606033
The immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease.Q40067370
Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunityQ40163840
Increased risk of cardiovascular events in patients with herpes zoster: a population-based studyQ44883715
Adverse Events in Cancer ImmunotherapyQ46884498
Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques?Q50140953
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysisQ56888890
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upQ57051777
Cancer statistics, 2019Q90941571
Hepatotoxicity and Recurrent NSTEMI While on Pembrolizumab for Metastatic Giant Cell Bone TumorQ91027542
P275copyright licenseCreative Commons Attribution-NonCommercial 4.0 InternationalQ34179348
P6216copyright statuscopyrightedQ50423863
P304page(s)1758835920913801
P577publication date2020-07-24
P1433published inTherapeutic advances in medical oncologyQ26842113
P1476titleNew disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event
P478volume12

Search more.